The regulatory role of DPP4 in atherosclerotic disease

Lihua Duan, Xiaoquan Rao, Chang Xia, Sanjay Rajagopalan, Jixin Zhong

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The increasing prevalence of atherosclerosis has become a worldwide health concern. Although significant progress has been made in the understanding of atherosclerosis pathogenesis, the underlying mechanisms are not fully understood. Recent studies suggest dipeptidyl peptidase-4 (DPP4), a regulator of inflammation and metabolism, may be involved in the development of atherosclerotic diseases. There has been increasing clinical and pre-clinical evidence showing DPP4-incretin axis is involved in cardiovascular disease. Although the cardiovascular outcome of DPP4 inhibition or incretin analogues has been or being evaluated by several large scale clinical trials, the exact role of DPP4 in atherosclerotic diseases is not completely understood. In the current review, we will summarize the recent advances in direct and indirect regulatory role of DPP4 in atherosclerosis.

Original languageEnglish (US)
Article number76
JournalCardiovascular Diabetology
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Dipeptidyl Peptidase 4
Incretins
Atherosclerosis
Cardiovascular Diseases
Clinical Trials
Inflammation

Keywords

  • Atherosclerosis
  • Dipeptidyl peptidase
  • DPP4 inhibitor
  • Gliptins
  • Incretin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

The regulatory role of DPP4 in atherosclerotic disease. / Duan, Lihua; Rao, Xiaoquan; Xia, Chang; Rajagopalan, Sanjay; Zhong, Jixin.

In: Cardiovascular Diabetology, Vol. 16, No. 1, 76, 01.01.2017.

Research output: Contribution to journalReview article

Duan, Lihua ; Rao, Xiaoquan ; Xia, Chang ; Rajagopalan, Sanjay ; Zhong, Jixin. / The regulatory role of DPP4 in atherosclerotic disease. In: Cardiovascular Diabetology. 2017 ; Vol. 16, No. 1.
@article{c05dcdf5c8e7467db92ca31ae41015ef,
title = "The regulatory role of DPP4 in atherosclerotic disease",
abstract = "The increasing prevalence of atherosclerosis has become a worldwide health concern. Although significant progress has been made in the understanding of atherosclerosis pathogenesis, the underlying mechanisms are not fully understood. Recent studies suggest dipeptidyl peptidase-4 (DPP4), a regulator of inflammation and metabolism, may be involved in the development of atherosclerotic diseases. There has been increasing clinical and pre-clinical evidence showing DPP4-incretin axis is involved in cardiovascular disease. Although the cardiovascular outcome of DPP4 inhibition or incretin analogues has been or being evaluated by several large scale clinical trials, the exact role of DPP4 in atherosclerotic diseases is not completely understood. In the current review, we will summarize the recent advances in direct and indirect regulatory role of DPP4 in atherosclerosis.",
keywords = "Atherosclerosis, Dipeptidyl peptidase, DPP4 inhibitor, Gliptins, Incretin",
author = "Lihua Duan and Xiaoquan Rao and Chang Xia and Sanjay Rajagopalan and Jixin Zhong",
year = "2017",
month = "1",
day = "1",
doi = "10.1186/s12933-017-0558-y",
language = "English (US)",
volume = "16",
journal = "Cardiovascular Diabetology",
issn = "1475-2840",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The regulatory role of DPP4 in atherosclerotic disease

AU - Duan, Lihua

AU - Rao, Xiaoquan

AU - Xia, Chang

AU - Rajagopalan, Sanjay

AU - Zhong, Jixin

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The increasing prevalence of atherosclerosis has become a worldwide health concern. Although significant progress has been made in the understanding of atherosclerosis pathogenesis, the underlying mechanisms are not fully understood. Recent studies suggest dipeptidyl peptidase-4 (DPP4), a regulator of inflammation and metabolism, may be involved in the development of atherosclerotic diseases. There has been increasing clinical and pre-clinical evidence showing DPP4-incretin axis is involved in cardiovascular disease. Although the cardiovascular outcome of DPP4 inhibition or incretin analogues has been or being evaluated by several large scale clinical trials, the exact role of DPP4 in atherosclerotic diseases is not completely understood. In the current review, we will summarize the recent advances in direct and indirect regulatory role of DPP4 in atherosclerosis.

AB - The increasing prevalence of atherosclerosis has become a worldwide health concern. Although significant progress has been made in the understanding of atherosclerosis pathogenesis, the underlying mechanisms are not fully understood. Recent studies suggest dipeptidyl peptidase-4 (DPP4), a regulator of inflammation and metabolism, may be involved in the development of atherosclerotic diseases. There has been increasing clinical and pre-clinical evidence showing DPP4-incretin axis is involved in cardiovascular disease. Although the cardiovascular outcome of DPP4 inhibition or incretin analogues has been or being evaluated by several large scale clinical trials, the exact role of DPP4 in atherosclerotic diseases is not completely understood. In the current review, we will summarize the recent advances in direct and indirect regulatory role of DPP4 in atherosclerosis.

KW - Atherosclerosis

KW - Dipeptidyl peptidase

KW - DPP4 inhibitor

KW - Gliptins

KW - Incretin

UR - http://www.scopus.com/inward/record.url?scp=85027580531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027580531&partnerID=8YFLogxK

U2 - 10.1186/s12933-017-0558-y

DO - 10.1186/s12933-017-0558-y

M3 - Review article

C2 - 28619058

AN - SCOPUS:85027580531

VL - 16

JO - Cardiovascular Diabetology

JF - Cardiovascular Diabetology

SN - 1475-2840

IS - 1

M1 - 76

ER -